<DOC>
	<DOCNO>NCT02015494</DOCNO>
	<brief_summary>One dose escalate strengths investigational influenza vaccine VAX2012Q ( Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine ) evaluate tolerability immunogenicity healthy adult 18-40 year age .</brief_summary>
	<brief_title>Phase 1 Safety Study Recombinant Influenza Vaccine Prevention</brief_title>
	<detailed_description>This multi-center , open-label , dose escalate study 320 healthy subject age 18-40 year administer VAX2012Q one 7 dose level . VAX2012Q vaccine formulate clinical site ( `` field mix '' ) four component ( VAX128C , VAX181 , VAX173 VAX172 ) diluent produce ten dose multi-dose vial use within 12 hour preparation . The dose prepared appropriate dilution monovalent drug product vial . Data safety immunogenicity collect dose safety assess dose level immune response , dose level 4 . Reactogenicity safety labs Day 1 review Safety Monitoring Committee ( SMC ) prior enrol next dose level .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>Males female age 1840 year age time vaccination good health determine medical history , physical exam , laboratory assessment clinical judgment Principal Investigator Able provide inform consent indicate understand purpose study willing adhere procedure describe protocol If subject female childbearing potential , must use adequate contraceptive precaution ( e.g. , intrauterine contraceptive device , oral contraceptive equivalent hormonal contraception ) 2 month prior vaccination continue use precaution minimum three month vaccination . She must also negative urine pregnancy test within 24 hour prior receive study vaccine . Women least one year postmenopausal surgically sterile consider childbearing potential . Willing receive unlicensed vaccine give IM injection Willing provide multiple blood specimen collect venipuncture Use investigational nonregistered drug vaccine product within 30 day precede administration study vaccine plan use within first six week study period Has receive license investigational influenza vaccine within 3 month prior enrollment study expect receipt influenza vaccination Day 21 blood collection History excessive alcohol use , drug abuse significant psychiatric illness Tobacco use within 3 month enrollment throughout first 6 month study Has chronic illness ( e.g. , liver kidney disease ) , receive concomitant therapy condition could interfere subject 's participation study interpretation study result Clinically significant abnormal liver function test screen Positive serology HBsAg , HCV HIV antibody Pregnant lactate female Having cancer receive treatment cancer within three year ( person history cancer diseasefree without treatment three year eligible ) , exclude minor skin cancer , allow unless locate vaccination site Persons impair immune responsiveness ( cause ) , include diabetes mellitus autoimmune disorder Persons presently receive recent history receiving ( within past six month ) medication therapeutic modality affect immune system allergy shot , immune globulin , interferon , immunomodulators , radiation therapy , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) . Inhaled topical corticosteroid allow . Persons history severe allergic reaction previous vaccination hypersensitivity seasonal influenza vaccine component Persons history GuillainBarré Syndrome Receipt blood blood product 8 week prior vaccination plan administration three week study period follow vaccination Donation blood blood product within 8 week prior vaccination three week study period follow An oral temperature &gt; 100.4° acute disease within 72 hour prior vaccination , define presence moderate severe illness ( determined investigator medical history physical examination ; example , require absence work ) without fever . Body Mass Index &gt; 29.9 Any disorder coagulation A clinical diagnosis influenza within previous 12 month Any condition circumstance , opinion Principal Investigator , pose unacceptable risk participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>